Home » Stocks » TRVN

Trevena, Inc. (TRVN)

Stock Price: $2.15 USD -0.05 (-2.05%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $2.20 +0.06 (2.56%) Feb 26, 7:51 PM
Market Cap 336.83M
Revenue (ttm) 3.03M
Net Income (ttm) -23.94M
Shares Out 144.34M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $2.15
Previous Close $2.19
Change ($) -0.05
Change (%) -2.05%
Day's Open 2.20
Day's Range 2.10 - 2.22
Day's Volume 2,501,379
52-Week Range 0.46 - 3.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 weeks ago

-- Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection regardless of age or body mass index, in exploratory analysis

Seeking Alpha - 1 month ago

Trevena's Catalyst-Filled Q1

GlobeNewsWire - 1 month ago

CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients ...

GlobeNewsWire - 2 months ago

-- P resentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy

GlobeNewsWire - 3 months ago

-- OLINVYK s ignificantly reduced risk of vomiting and rescue antiemetic use compared to IV morphine in a retrospective analysis

Seeking Alpha - 3 months ago

OLINVYK is headed for commercial availability, likely by Q1 '21, even though distribution can occur as early as late November following DEA scheduling. Trevena still has a busy 2021 full of ca...

GlobeNewsWire - 3 months ago

-- Guggenheim Healthcare Talks - 2nd Annual Neuro/Immunology Day Conference November 16 th Stifel Virtual Healthcare Conference November 1 8 th

GlobeNewsWire - 3 months ago

-- OLINVYK commercial supply on track and available in November

Zacks Investment Research - 4 months ago

Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.

Zacks Investment Research - 4 months ago

Is (TRVN) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 4 months ago

-- Posters highlight improvements in respiratory safety and gastrointestinal tolerability associated with OLINVYK (oliceridine) injection vs. IV morphine

Zacks Investment Research - 4 months ago

As of late, it has definitely been a great time to be an investor in Trevena.

GlobeNewsWire - 5 months ago

-- Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.

The Motley Fool - 5 months ago

An analyst initiates coverage on the stock with an unequivocal buy recommendation.

GlobeNewsWire - 5 months ago

- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th

Seeking Alpha - 5 months ago

Trevena: Strong Buy After Opioid Approval And Potential Supplementary COVID-19 Value

Benzinga - 5 months ago

Trevena (NASDAQ: TRVN) shares are trading higher on Friday after Cantor Fitzgerald initiated coverage on the company's stock with an Overweight rating and announced a $5 price target.

GlobeNewsWire - 6 months ago

-- Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis

Benzinga - 6 months ago

Trevena (NASDAQ: TRVN) shares traded higher on Monday after the company announced the initiation of its TRV027 study in COVID-19 patients in collaboration with Imperial College London.

GlobeNewsWire - 6 months ago

-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19

GlobeNewsWire - 6 months ago

-- $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

CHESTERBROOK, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with c...

The Motley Fool - 6 months ago

The biopharmaceutical company announced the pricing of a public offering of common stock.

GlobeNewsWire - 6 months ago

CHESTERBROOK, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization o...

GlobeNewsWire - 6 months ago

CHESTERBROOK, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patient...

The Motley Fool - 6 months ago

The biotech's innovative painkiller is the first new drug in its class in decades.

GlobeNewsWire - 6 months ago

OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic

Zacks Investment Research - 7 months ago

Trevena (TRVN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain

GlobeNewsWire - 8 months ago

-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung injury and ARDS

Zacks Investment Research - 9 months ago

Is (TRVN) Outperforming Other Medical Stocks This Year?

Seeking Alpha - 9 months ago

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Is (TRVN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 10 months ago

Trevena has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Seeking Alpha - 11 months ago

Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.

GlobeNewsWire - 11 months ago

FDA considers NDA resubmission a complete Class 2 response

GlobeNewsWire - 1 year ago

CHESTERBROOK, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patient...

Zacks Investment Research - 1 year ago

Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.

GlobeNewsWire - 1 year ago

Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain

GlobeNewsWire - 1 year ago

CHESTERBROOK, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patient...

GlobeNewsWire - 1 year ago

Safety, tolerability, and PK profile support potential utility as a novel acute migraine treatment option

Seeking Alpha - 1 year ago

Trevena: Don't Get Hooked On This One

GlobeNewsWire - 1 year ago

No dose adjustments required for patients with renal impairment or patients with mild / moderate hepatic impairment

GlobeNewsWire - 1 year ago

Safety and tolerability demonstrated in diverse patient populations and surgeries

GlobeNewsWire - 1 year ago

CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patient...

GlobeNewsWire - 1 year ago

CHESTERBROOK, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patient...

GlobeNewsWire - 1 year ago

CHESTERBROOK, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patien...

About TRVN

Trevena, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2014
CEO
Carrie Bourdow
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
TRVN
Full Company Profile

Financial Performance

In 2019, Trevena's revenue was $31,000, a decrease of -99.46% compared to the previous year's $5.73 million. Losses were -$24.87 million, -19.21% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Trevena stock is "Buy." The 12-month stock price forecast is 5.25, which is an increase of 144.76% from the latest price.

Price Target
$5.25
(144.76% upside)
Analyst Consensus: Buy